| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Ganaxolone (USAN/INN); Ztalmy (TN) | ||||||||||
| Product | ZTALMY (Marinus Pharmaceuticals) | ||||||||||
| Formula | C22H36O2 | ||||||||||
| Exact mass | 332.2715 | ||||||||||
| Mol weight | 332.52 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Metabolizing enzyme substrate DG02919 CYP2B6 substrate DG01639 CYP2C19 substrate DG01644 CYP2D6 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG02925 CYP3A5 substrate | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antiepileptic, Antimigraine | ||||||||||
| Disease | Seizures associated with cyclin-dependent kinase-like 5 deficiency disorder [DS:H01819] | ||||||||||
| Comment | Allopregnanolone [CPD:C15484] analog Treatment of epilepsy and migraine | ||||||||||
| Target | GABR [HSA:2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 55879] [KO:K05175 K05181 K05184 K05185 K05186 K05189 K05192] | ||||||||||
| Pathway |
| ||||||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576], CYP3A5 [HSA:1577], CYP2B6 [HSA:1555], CYP2C19 [HSA:1557], CYP2D6 [HSA:1565] | ||||||||||
| Interaction | |||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N03 ANTIEPILEPTICS N03A ANTIEPILEPTICS N03AX Other antiepileptics N03AX27 Ganaxolone D04300 Ganaxolone (USAN/INN) <US> Drug groups [BR:br08330] Metabolizing enzyme substrate DG02919 CYP2B6 substrate D04300 Ganaxolone DG01639 CYP2C19 substrate D04300 Ganaxolone DG01644 CYP2D6 substrate D04300 Ganaxolone DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D04300 Ganaxolone DG02925 CYP3A5 substrate D04300 Ganaxolone Target-based classification of drugs [BR:br08310] Ion channels Ligand-gated ion channels GABA (ionotropic) GABR D04300 Ganaxolone (USAN/INN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D04300 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D04300 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D04300 Pharmacogenomic biomarkers [br08341.html] Germline mutations in genetic disorder treatments D04300 | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 24 1 C1x C 38.1743 -26.7423 2 C1z C 38.1743 -28.1094 3 C1x C 39.3363 -28.7930 4 C1y C 40.5668 -28.1094 5 C1z C 40.5668 -26.7423 6 C1x C 39.3363 -26.0587 7 C1x C 41.7288 -28.7930 8 C1x C 42.8909 -28.1094 9 C1y C 42.8909 -26.7423 10 C1y C 41.7288 -26.0587 11 C1y C 44.1213 -26.0587 12 C1z C 44.1213 -24.6916 13 C1x C 42.8909 -24.0080 14 C1x C 41.7288 -24.6916 15 C1a C 40.5668 -25.3751 16 C1a C 44.1213 -23.3244 17 C1a C 36.8071 -28.1094 18 O1a O 37.8325 -29.4082 19 C1x C 46.5138 -26.0587 20 C1x C 46.5138 -24.6916 21 C1y C 45.2834 -24.0080 22 C5a C 45.2666 -22.6410 23 C1a C 44.0870 -21.9792 24 O5a O 46.4544 -21.9354 BOND 27 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 1 7 4 7 1 8 7 8 1 9 8 9 1 10 9 10 1 11 5 10 1 12 9 11 1 13 12 13 1 14 13 14 1 15 10 14 1 16 5 15 1 #Up 17 12 16 1 #Up 18 2 17 1 #Up 19 2 18 1 #Down 20 11 19 1 21 19 20 1 22 20 21 1 23 21 22 1 #Up 24 22 23 1 25 22 24 2 26 21 12 1 27 12 11 1 |